

The Changing Face of Complicated Pneumonia in the Era of Pneumococcal Conjugated Vaccine

Philadelphia ATS 2020

Andrew Colin, MD

Batchelor Family Professor of Cystic Fibrosis and
Pediatric Pulmonology
Director, Division of Pediatric Pulmonology

Pneumonia

(lower respiratory infection - LRI)

- A highly prevalent entity in childhood
- The largest single cause of morbidity and mortality worldwide in children <5 years outside the neonatal period
- Statistics from the western world suggest an annual incidence of 3-4% of the pediatric population below age 5, a substantially higher incidence than in adults
- It is important to acknowledge that the review today may not be reflective of large low-income parts of the world

Table 2. Complications Associated With Community-Acquired Pneumonia

Pulmonary

Pleural effusion or empyema

~~Pneumothorax~~

Lung abscess

Bronchopleural fistula

Necrotizing pneumonia

Acute respiratory failure

Metastatic

Meningitis

Central nervous system abscess

Pericarditis

Endocarditis

Osteomyelitis

Septic arthritis


Systemic

Systemic inflammatory response syndrome or sepsis


Hemolytic uremic syndrome

Community-Acquired Pneumonia Hospitalization - U.S. Children

B Specific Pathogens Detected



C Detection According to Age Group



Pleural effusion in Children

Empyema

literally means

“purulent appearing” = “it looks like pus”

It is loosely used as

“predictor of complicated outcome”

Ultrasound for pleural effusion



Complex septated pleural effusion

Timing is crucial Intervention should occur before the effusion is organized


The Sun Should Never Set on a Parapneumonic Effusion

It has been documented that pleural effusions are frequently associated with pneumonia, whether it be pneumococcal, staphylococcal, Gram-negative aerobic, or anaerobic.^{1,2} The most common cause of an empyema or complicated parapneumonic effusion today is anaerobic pulmonary infection.³ This is largely related to the pathogenesis of anaerobic pulmonary infection, since the disease frequently occurs in the alcoholic patient or in those with impaired conscious-

Stages Of Parapneumonic Exudate

- *exudative* phase

free flow, low cellularity







48-72 hours


- *fibropurulent* phase

fibrin accumulation, abundant PMN -
loculation occurs

- *organizing* phase

fibroblastic activity, “peel” formation





Predictors Of Complicated Outcome Of Pleural Effusion

The hierarchy that emerges from the literature as to the relative efficacy of individual pleural fluid parameters to predict complicated outcome of pleural effusion




pH
Glucose
LDH
Cell count

Pleural effusion

- Pleural effusions are a frequent complication of childhood pneumonia
- Opinions regarding diagnosis and treatment of pleural effusion vary widely
 - ABX therapy/delay pleural tap
(Epaud 2006, Carter 2010)
 - Thrombolysis w pigtail drain
(Thomson 2001, Balfour-Lynn 2005)
 - Early video-assisted thoracoscopy
(Schultz 2004)
 - Repeated U/S-guided needle thoracocentesis
(Shoseyov 2002)

Urokinase vs. VATS for Childhood Empyema flow diagram



Urokinase vs. VATS for Childhood Empyema Primary End Point

No clinically significant difference in hospital stay
between the two groups

($p = 0.311$, 95% CI of the median difference, - 2 to 1).


Median post-intervention hospital stay

VATS 6 d (range, 3–16 d)

Urokinase 6 d (range, 4–25 d)


Pathway for evaluation and management of parapneumonic effusion in children

Improvement is assessed clinically (child feels better, becomes more active, temperature and inflammatory markers fall)



Legenda: PCR: Polymerase Chain Reaction; CXR: chest radiography; US: ultrasound; CT: computed tomography; VATS: video assisted thoracoscopic surgery;
* "Primary" VATS may be considered in a very advanced organizing stage

Empyema hospitalizations increased in US Children despite pneumococcal conjugated vaccine



Empyema- associated hospitalization rates / 100,000 children

Necrotizing or Cavitating Pneumonia Due to *Streptococcus pneumoniae*:


Medicine, 1980

REPORT OF FOUR CASES AND REVIEW OF THE LITERATURE

BIENVENIDO G. YANGCO, M.D., M.P.H. AND STANLEY C. DERESINSKI, M.D.¹

**Necrotizing
Pneumonia**

(Massive Pulmonary Gangrene)



Bacteremic Necrotizing Pneumococcal Pneumonia in Children

AM J RESP CRIT CARE MED, 1994

**EITAN KEREM, YAACOV BAR ZIV, BERNARD RUDENSKI, SHMUEL KATZ, DAVID KLEID,
and DAVID BRANSKI**

Departments of Pediatrics, Pulmonary and Cystic Fibrosis Clinic, and Clinical Microbiology, Shaare Zedek Medical Center,
and Departments of Radiology and Pediatric Surgery, Hadassah Medical Center, Jerusalem, Israel

- First description of 4 cases of necrotizing pneumonia in childhood
- Ages ranged 1 – 7.5 years
- Presentation with bacteremic pneumococcal pneumonia

Bacteremic Necrotizing Pneumococcal Pneumonia in Children

EITAN KEREM, YAACOV BAR ZIV, BERNARD RUDENSKI, SHMUEL KATZ, DAVID KLEID,
and DAVID BRANSKI

- Pulmonary parenchymal liquefaction and necrosis was determined by CT scan
- The clinical course was prolonged with fever lasting up to 20 days and hospitalization up to 26 days
- Contrary to adults, complete recovery was noted and no invasive investigation required

National Hospitalization Trends for Pediatric Pneumonia and Associated Complications

Grace E. Lee, Scott A. Lorch, Seth Sheffler-Collins, Matthew P. Kronman and Samir S. Shah

Rates of CAP

TABLE 3 Rates of CAP in 1997–2006, Stratified According to Age

Age	1997		2000		2003		2006		Change, 1997 vs 2006, %
	<i>n</i> (%)	Rate, Estimate (95% CI), Cases per 100 000	<i>n</i> (%)	Rate, Estimate (95% CI), Cases per 100 000	<i>n</i> (%)	Rate, Estimate (95% CI), Cases per 100 000	<i>n</i> (%)	Rate, Estimate (95% CI), Cases per 100 000	
<1 y	43 851 (30)	1169.0 (1158.2–1179.9)	44 691 (28)	1159.1 (1148.4–1169.8)	37 798 (24)	937.6 (928.2–947.0)	37 705 (24)	912.9 (903.8–922.1)	-21.9
1–5 y	75 033 (50)	383.1 (380.3–385.8)	76 775 (48)	397.7 (394.9–400.5)	77 530 (49)	395.6 (392.8–398.4)	79 519 (51)	390.4 (387.7–393.2)	1.9
6–12 y	19 372 (13)	69.3 (68.3–70.2)	21 531 (14)	74.1 (73.1–75.1)	23 126 (15)	80.9 (79.9–82.0)	23 494 (15)	84.5 (83.4–85.6)	21.9
13–18 y	10 446 (7)	44.7 (43.8–45.5)	15 663 (10)	64.7 (63.6–65.7)	19 289 (12)	77.1 (76.1–78.2)	16 092 (10)	62.8 (61.9–63.8)	40.5

Rates are reported as cases per 100 000 age-specific US population.

Rates of CAP – associated complications: Overall

TABLE 2 Rates of CAP and Associated Complications in 1997–2006






	1997	2000	2003	2006	Change, 1997 vs 2006, %
CAP discharges, estimate (95% CI), cases per 100 000	199.1 (198.1–200.1)	207.6 (206.6–208.6)	204.3 (203.1–205.3)	201.2 (200.2–202.2)	1.1
Any complication					
Rate, estimate (95% CI), cases per 100 000	11.8 (11.6–12.1)	14.6 (14.3–14.8)	15.8 (15.3–15.8)	15.1 (14.8–15.3)	28.0
Proportion of CAP cases, %	5.9	7.0	7.7	7.5	
Local complications					
Rate, estimate (95% CI), cases per 100 000	5.4 (5.2–5.6)	7.4 (7.2–7.6)	8.9 (8.6–9.0)	9.6 (9.4–9.9)	77.8
Proportion of CAP cases, %	2.7	3.6	4.4	4.8	
Systemic complications					
Rate, estimate (95% CI), cases per 100 000	6.8 (6.6–7.0)	7.7 (7.5–7.9)	7.5 (7.3–7.7)	6.2 (6.0–6.3)	-8.8
Proportion of CAP cases, %	3.4	3.7	3.7	3.1	

Rates are reported as cases per 100 000 age-specific US population.

Local – empyema, lung abscess, necrotizing pneumonia, or bronchopulmonary fistula

Systemic – acute resp. failure, sepsis, ECMO, or HUS

Rates of CAP – associated complications: By age



Following the introduction of PCV7 in 2000

- **Rates of CAP:**
 - Decreased for infants <1yo
 - Increased for children >5 yo
- **Systemic complications:**
 - Decreased for infants <1yo
- **Local complications:**
 - Increased for all age groups

NECROTIZING PNEUMONIA

Unknown organism assumed
S. pneumoniae


- 3 year and 9 month old girl admitted with fever, cough, respiratory distress
- Five days of nasal congestion, cough, fever to 39°C and worsening dyspnea
- Refused to get out of bed for 2 days
- Was not seen by MD, parents considered this to be URI. Received no oral antibiotics

December 25



- Ultrasound of the chest to determine effusion revealed minimal amount, not tapped
- Assumed most likely
Strep. pneumoniae, possibly
Staph. aureus.
Started on high dose intravenous
ampicillin - sulbactam


December 28
(Day IV)




December 28

(Day IV)

CT with contrast




December 31
(Day VI)




December 31

(Day VI)



Large irregular
pneumatocele

No wall



Note the rapid transition from necrosis to cavitation


January 3
(Day IX)



January 3



(Day IX)

CT with contrast



January 19

(Day XXV)







May 9

4 months later




September 7



January 3



September 7



Necrotising pneumonia is an increasingly detected complication of pneumonia in children


Eur Resp J, 2008

G.S. Sawicki^{*,+}, F.L. Lu^{*,+}, C. Valim[#], R.H. Cleveland[¶] and A.A. Colin^{*}

The largest study of necrotizing pneumonia published to date



Children's Hospital Boston
Harvard Medical School



Necrotizing Pneumonia

Children's Hospital Boston (1990-2005)

- The **electronic database** of the Department of Radiology was reviewed for **1/1990-2/2005**
- All **CT scans** with the term "**necrotizing**" in the full radiologic report
- All reports were inspected to identify misleading terms such as "no evidence of necrotizing pneumonia"
- The **senior Radiology author** (RHC) then **screened each individual scan** to determine whether there was imaging evidence of necrotizing pneumonia present

Necrotizing Pneumonia

Children's Hospital Boston (1990-2005)

Demographics

- We identified a total of **80** cases of community acquired necrotizing pneumonia during the study period from January 1, 1990 through February 28, 2005
- **No identified** cases between **1990-1993**
- The median age was **3.6 years** (range 0.25-19)
- **53%** were male

Necrotizing Pneumonia


Children's Hospital Boston (1990-2005)

Clinical features



- Ninety-six percent of patients reported an initial symptom of high fever
- 84% reported cough
- 91% were seen by a doctor prior to admission
- 53% required oxygen supplementation for at least one hospital day
- mean duration of fever 6 d (range 5-27)
- Mean length of stay 15 d (range 3-84)
- Mean duration of antibiotics 13 d (range 3-95)

NP Cases Per Year

- Zero cases were detected between 1990-1993




Newcastle upon Tyne Cavitary disease per year



Ramphul, Ped Pulmonol, 2006

Children's Hospital Boston 1990-2004


Zero cases were detected
between 1990-1993



Sawicki, Lu et al, Eur Resp J, 2008

Necrotizing Pneumonia in Children: Report of 41 Cases Between 2006 and 2011 French Tertiary Care Center.

Hôpital Robert-Debre



Queensland, Australia, 2017

Masters *et al. Pneumonia* (2017) 9:11
DOI 10.1186/s41479-017-0035-0

Pneumonia

REVIEW

Open Access




Necrotizing pneumonia: an emerging problem in children?


I. Brent Masters¹, Alan F. Isles¹ and Keith Grimwood^{2,3*}

This study estimated NP to complicate up to 7% of pediatric CAP admission


Necrotizing Pneumonia – Underlying mechanisms



Kidney



Is this a vasculopathy?




Kamran M



Kamran M

R

L




5mm/div

Blue= Effusion

Gray= necrotic lung

Pink= consolidated or atelectatic (non-necrotic) intact lung




Kamran M

Necrotizing Pneumonia

Conclusions


Incidence and course

- We think that necrotizing pneumonia is a more common condition than appreciated
- CT scan is required to establish the diagnosis with confidence
- Similar to previous reports, our study reveals that the clinical course is typically prolonged and often complicated




Microbiology


No causative organism was identified in 42/80 cases



- Positive cultures were obtained in 38/80 (48%) cases
- Pleural fluid culture had the highest yield
- *Pneumococcus* was isolated in 18/80 (23%) cases



Microbiology



NECROTIZING PNEUMONIA

4-month-old

Organism


Methicillin Resistant *S. aureus*
(MRSA)

Gabriella M




11-8

Gabriella M



11-12

Gabriella M




11-12

Gabriella M



11-12



Gabriella M



11-22

Gabriella M

12-2



Gabriella M



2-2-05

Staph aureus and PVL in NP

- S. aureus has many virulence factors
- Of these, **Panton-Valentine leukocidin (PVL)** is most notable in our context
- PVL is a pore-forming exotoxin, activates and then destroys immune cells, such as neutrophils, with release of damaging proteases into lung milieu
- Often with MRSA


Multicenter French study, NP with PVL

- mixed child-adult (median age was 14.5 years (interquartile range 1.8-36 yrs))
- The overall mortality rate was **56%**, and the median survival was 10 days

Gillet, Clin Infect Dis, 2007

Microbiology

No causative organism was identified in 42/80 cases



Novel technologies to overcome low yield of cultures






- Molecular diagnostic tests, based on amplification of DNA and detection of specific genes, have been a major advance in the diagnosis of respiratory infections
- PCR is less affected by antimicrobial therapy than culture techniques; it also offers the advantage of providing results and serotyping within a few hours
- Several studies have shown that PCR of blood and pleural fluid is significantly more sensitive than culture in identifying pathogens in pediatric empyema especially in the context of preceding antibiotic treatment

Taiwan



- 5 cases of necrotizing pneumonia
- Ages ranging 3 - 14 years of age
- All with pleural effusion
- All tested positive for
Mycoplasma pneumoniae
- Sequelae:
 - 3 full resolution
 - 1 persistent atelectasis
 - 1 persistent pneumatocele at 180 days follow-up

Mycoplasma pneumoniae-
associated
necrotizing
pneumonitis



(China)



Lung abscess vs necrotizing pneumonia



Lung abscess vs necrotizing pneumonia



Complicated pneumonia - Treatment

- Treatment is with a prolonged course of intravenous followed by oral antibiotics
- The initial choice is guided by local microbiological knowledge followed by subsequent positive cultures and molecular testing, importantly on pleural fluid when available
- Duration of therapy is conventionally prolonged, but no data are available for comparisons

Pneumococcal Conjugate Vaccine


- PCV7 was designed to protect against the most common serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) that cause invasive pneumococcal disease in children
 - Meningitis
 - Bacteremia
 - Pneumonia

By the end of 2007, estimated coverage with 3 - 4 doses of PCV7 among U.S. children aged 19-35 months was 90% and 76% respectively


Centers for Disease Control and Prevention
The National Center for Health Statistics
The National Immunization Survey

In a large multicenter study on admission with *S. pneumoniae*
 The prevailing serotypes causing disease were
 1, 6, 14, 19 which were **NOT** covered by the
 pneumococcal conjugated vaccine

Uncomplicated Pneumonia




Complicated Pneumonia



Necrotizing pneumonia - an **increasing** complication of community acquired pneumonia in childhood

Andrew Colin, M.D.
Boston Children's Hospital
Harvard Medical School




Necrotising pneumonia is an increasingly detected complication of pneumonia in children

Eur Resp J, 2008

G.S. Sawicki^{*,+}, F.L. Lu^{*,+}, C. Valim[#], R.H. Cleveland[¶] and A.A. Colin^{*}



Children's Hospital Boston
Harvard Medical School



Queensland, Australia, 2017

Masters *et al. Pneumonia* (2017) 9:11
DOI 10.1186/s41479-017-0035-0

Pneumonia

REVIEW

Open Access

Necrotizing pneumonia: an emerging problem in children?



I. Brent Masters¹, Alan F. Isles¹ and Keith Grimwood^{2,3*}

Increase of necrotizing pneumonia after PCV-7

- Retrospective analysis 1/97 – 3/06 for all pneumococcal pneumonias <18 yo in a tertiary center
- 124 children identified
- 33 (27%) of these had radiographic evidence of NP
 - 1997–2000, 5/39 (13%) had PNP
 - 2001–2006, 28/85 (33%) had NP
(OR, 3.34; 95% CI, 1.11–12.03)

Increase of necrotizing pneumonia after PCV-7

- Non-PCV-7 serotypes:
 - 1997–2000 - 49%
 - 2001–2006 - 88%(OR, 7.89; 95% CI, 2.91–21.90)
- **Serotype 3** most often associated with NP
 - 11/14 (79%) cases of serotype 3-associated pneumonia were associated with PNP
 - Compared with all other serotypes, serotype 3 was strongly associated with NP(OR, 14.67; 95% CI, 3.39–86.25)

Serotype replacement in disease after pneumococcal vaccination

Daniel M Weinberger

Richard Malley

Marc Lipsitch

Epidemiology of post PCV7 vaccination *Serotype replacement*

- There is strong evidence that colonization with Non-vaccine types (NVTs) increases in vaccinated populations
- Non-vaccine types (NVTs) have increased among asymptomatic carriers in a process dubbed “serotype replacement”
- To a lesser extent, NVTs have increased as causes of invasive pneumococcal disease (IPD)

Enter PCV 13

- Starting 2010
- 6 capsular antigens of serotypes
1, 3, 5, 6A, 7F, and 19A


were added to those included in

- PCV7
4, 6B, 9V, 14, 18C, 19F and 23F


With very effective reduction of Invasive Pulmonary
Diseases (IPD) in children in the US

Moore, Lancet Respir Med, 2016


Rates of invasive pneumococcal disease Children <5 years of age, 1998–2015



Annual trends in Invasive Pulmonary Diseases (IPD) children < 5 yrs 2006-13



Cumulative cases of PCV5-type IPD Children <5 yrs (2006-2013)



“PCV5” types include those in PCV13 but not in PCV7.

National Cases & Deaths of IPD Prevented following PCV13 Introduction 2010 - 2013


~ 30,000 cases prevented


■ <5 ■ 5 to 17 ■ 18 to 49 ■ 50 to 64 ■ >64



~ 3,000 deaths prevented


■ <5 ■ 5 to 17 ■ 18 to 49 ■ 50 to 64 ■ >64





Annual 7VT,
13VT and non-
13VT serotype
IPD rates in
Israeli children
<5years

Annual serotype-specific IPD rates in children <5 years, Israel 2004-2013






photo: Hans Peter Herten/Corbis Eyenews/Getty Images

non smoking area

Necrotizing Pneumonia

Pleural complications

- Children with necrotizing pneumonia mostly present as complicated **pleuro**pneumonia
- Pleural effusion is the **initial** therapeutic challenge in this complex disease
- The recognition that a necrotizing pneumonia complicates the disease comes late in the course, when the treatment for the pleural disease is ongoing but symptoms persist
- It is the pleural element that typically extends the course

Fredric A. Hoffer
David A. Bloom
Andrew A. Colin
Steven J. Fishman

Lung abscess versus necrotizing pneumonia: implications for interventional therapy

- In our study 5 of 9 children with necrotizing pneumonia developed **bronchopleural fistulae** following chest tube placement. None with abscess developed such complication
- We concluded that the placement of chest tubes **probably increases** the risk of fistula formation in the presence of necrotizing pneumonia, and may extend the duration of the disease

Necrotizing Pneumonia

Children's Hospital Boston (1990-2005)


Pleural complications/Surgery

- 83% of the patients had pleural effusion
- 76% had pleural drainage
- Median duration of drainage 6 d (range 1-52)
- 15% had surgical intervention



- 10 patients (12.5%) developed bronchopleural fistula during the course of treatment
- All these patients had pleural drainage greater than 7 days
- One patient had a partial lobectomy

JR Day 12


CT with contrast



JR 13 months



CM 6-11-05



Necrotizing Pneumonia

Pleura - Conclusions

The necrotizing pneumonia – empyema conundrum

- Given that 83% of the cases in our series had a pleural effusion, a serious conundrum emerges, namely, whether the severe morbidity conventionally attributed to empyema may in reality reflect necrotizing pneumonia
- No study ever attempted to uncouple coexisting pleural effusion and necrotizing pneumonia

Necrotizing Pneumonia

Pleura - Conclusions

Length of treatment of pleural effusion

- The treatment of pleural effusion in the face of NP may require a more cautious approach; attempting to minimize drainage time because of risk of bronchopleural fistulae
- We think that the incidence of bronchopleural fistulae has decreased since we have become more conservative in the use of pleural drains



Necrotizing Pneumonia

Conclusions

NP vs. Lung abscess

- It is an enormous error to view necrotizing pneumonia as a lung abscess
- In particular if this will lead to manipulation and attempted drainage of the “abscess”
- This is almost guaranteed to lead to bronchopleural fistula and complicate the care and outcome


Necrotizing Pneumonia

Late pleural complications


On the Nature of Pleural Involvement in Necrotizing Pneumonia: A Report of Two Cases of Life Threatening Late Complications

**Nadir Demirel, MD,^{1*} Annabelle Quizon, MD,¹ Edgar Leonel Beltetón De Leon, MD,² Joel Reiter, MD,¹
and Andrew A. Colin, MD¹**


DT – 1 year old 11/3




DT – 1 year old 11/8



DT – 1 year old 11/15




DT – 1 year old 11/17




DT – 1 year old 11/17



DT – 1 year old 11/17




DT – 1 year old 11/17




DT – 1 year old

- Discharged on 11/24 to complete a total of 4 weeks of antibiotics with follow up by Pediatric Pulmonology
- She was not seen because of insurance issues
- She returned on 12/28 to the Pedi ER for fever, cough, and increased WOB for 1 day
- Completed antibiotics 3 weeks prior

DT – 1 year old 12/28



DT – 1 year old 12/29




DT – 1 year old 1/8/11



DT – 1 year old 1/8/11



DT – 1 year old 1/8/11



DT – 1 year old 1/8/11



Necrotizing Pneumonia

Conclusions

The residual cavity – pneumatocele vs. pneumothorax
conundrum

- Many patients are discharged with residual cavities after admission with NP
- These cavities are referred to as pneumatoceles and are viewed as risk free
- Many of these cavities may in reality represent loculated pneumothoraces and as such may have late complications
- Should discharge orders for parents be modified accordingly?